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Abstract 
Purpose: We aimed to assess the usefulness of positron emission tomography (PET) using the amino acid tracer 
L-3-[18F] fluoro-alpha-methyl tyrosine (FAMT) in detecting metastatic liver lesions compared with 2-[18F]-fluoro-
2-deoxyglucose (FDG).
Methods: We included 24 patients with liver metastases who underwent both FDG-PET/computed tomography (CT) 
and FAMT-PET/CT. Maximum standardized uptake value (SUVmax) and tumor-to-liver parenchymal (T/L) ratio were 
analyzed to evaluate the correlation between FDG and FAMT uptakes in metastatic liver lesions; adenocarcinoma 
(AC, n = 21), squamous cell carcinoma (SCC, n = 23), neuroendocrine tumor (NET, n = 9), and carcinoid tumor (CAR, 
n = 6).
Results: We detected 59 lesions on performing either FDG-PET or FAMT-PET. NETs had significantly lower T/L ratios 
for FAMT (median, 1.00; range, 0.86–1.34) compared with those for FDG (median 2.86; range 1.70–6.13, p < 0.01). CAR 
tumors tended to reveal lower T/L ratios for FDG (median 1.10; range 0.78–1.92) than those for FAMT (median 1.80; 
range 0.80–2.34). Comparison of T/L ratios of SCC and AC revealed that FAMT in the metastatic liver lesions of SCC was 
higher than those of AC (p < 0.05).
Conclusion: FAMT-PET could detect metastatic liver lesions from various cancers, except NET.
Keywords: Liver metastasis, L-3-[18F] fluoro-alpha-methyl tyrosine, 2-[18F]-fluoro-2-deoxyglucose, Positron emission 
tomography
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Background
Involvement of the liver as a site of cancer metastasis 
causes significant problems in morbidity and mortal-
ity. Because liver dysfunction due to the poor control of 
liver metastasis would shorten patient survival period, 
the assessment of metabolic function of the liver with 
metastasis is an important prognostic tool (Wiering et al. 
2005; Bonanni et al. 2014; Fernandez et al. 2004).
Positron emission tomography (PET) using an 
18F-labeled glucose analog, 2-[18F]-fluoro-2-deoxyglu-
cose (FDG) is the most sensitive imaging method to 
detect malignant lesions that utilize glucose at greater 
rates than normal tissue because of an increase in both 
glucose transport and metabolism through the glucose 
transporter (GLUT1) (Juweid and Cheson 2006). Because 
metastatic liver lesions have little or no glucose-6-phos-
phatase, FDG is trapped within the cell (Mamede et  al. 
2005; Okazumi et  al. 1992). Therefore, FDG-PET scans 
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reveal that metastatic liver lesions have a high FDG 
uptake.
Many clinical studies revealed the feasibility of FDG-
PET for diagnosing, staging, treatment monitoring, and 
detecting recurrent malignant tumors (Fischer et  al. 
2009; Pieterman et  al. 2000; Kostakoglu and Goldsmith 
2003). The detection of liver metastasis from colorectal 
and other gastrointestinal cancers has been evaluated 
in many reports; most of them addressed the very high 
sensitivity of FDG-PET in detecting liver metastasis com-
pared with other modalities, such as computed tomogra-
phy (CT) and magnetic resonance imaging (MRI), by the 
administration of conventional contrast agents (Kinkel 
et al. 2002; Bipat et al. 2005). Currently, MRI using gado-
linium-ethoxybenzyl-diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA) has shown very high detectability for 
hepatic lesions. However, FDG-PET still has the advan-
tage for detecting liver lesions. In contrast, the sensitiv-
ity of FDG-PET was not good, particularly for small liver 
lesions. The reasons would be the poor spatial resolution 
of PET and that FDG uptake in normal parenchymal tis-
sue would obscure small liver lesions without high-FDG 
uptake. In addition, differentiation between inflamma-
tion and tumor lesions is difficult for FDG-PET (Nishii 
et al. 2013; Yamada et al. 1998; Morita et al. 2013). Never-
theless, FDG-PET still plays an important role in detect-
ing metastatic liver lesions in a clinical setting.
It also is well known that amino acid tracers also accu-
mulate in cancer lesions. In contrast to FDG, amino acid 
tracers do not accumulate in inflammatory lesions and 
the specificity of amino acid tracers to malignant lesions 
is reliable compared with that of FDG(Inoue et al. 1999, 
2001). Tumor cells require amino acid transporters such 
as L-amino acid transporter type 1 (LAT1) (Kaira et  al. 
2008; Namikawa et  al. 2015). In our facility, we devel-
oped L-3-[18F] fluoro-alpha-methyl tyrosine (FAMT) as 
an amino acid PET tracer(Tomiyoshi et  al. 1997). The 
specific accumulation of FAMT in malignant tumors has 
been evaluated in a clinical setting and has been demon-
strated to be useful in the diagnosis of various types of 
malignant tumors. With regard to the detection of lesions 
in the liver, because the most investigated amino acid 
tracers, 11C-methionine (MET) and anti-1-amino-3-18F-
fluorocyclobutane-1-carboxylic acid (FACBC), accumu-
late in both cancerous and normal liver cells, their uptake 
in the normal liver tissue is strong enough to obscure the 
accumulation in metastatic lesions. In contrast, FAMT 
uptake in a normal liver has been known to be low, mak-
ing FAMT a good candidate to detect metastatic liver 
lesions.
In this study, the accumulations of FDG and FAMT in 
metastatic liver lesions were compared and correlated 
with their respective histological features.
Methods
Patients
This retrospective study included 24 patients (17 men 
and seven women; aged 32–85 years; mean 67 years) with 
advanced cancer complicated by liver metastases who 
had undergone both FDG-PET/CT and FAMT-PET/CT 
between August 2007 and November 2014. The inclusion 
criteria were as follows: (1) <1-month interval between 
FDG-PET/CT and FAMT-PET/CT scans and (2) none 
of the metastatic lesions received treatment. Patients 
with duodenal pleomorphic sarcoma (n  =  1), malig-
nant lymphoma (n =  2), and lung small cell carcinoma 
(n = 3) were excluded from this study because the num-
ber of patients with liver metastasis for each group was 
only one. Blood samples were taken before tracer injec-
tion and an acceptable blood sugar level (<200  mg/dl) 
was confirmed. This study was reviewed and approved by 
our institutional review board, and informed consent was 
obtained from all patients.
PET tracer administration
Both FDG and FAMT were synthesized in the cyclotron 
facility of our institute; FAMT was synthesized according 
to the method of Tomiyoshi et al. Briefly, L-alpha-meth-
yltyrosine was fluorinated by [18F]-acetylhypofIuoride, 
and the separation and purification of FAMT were per-
formed by a remote control system (Tomiyoshi et  al. 
1997). Patients were intravenously injected with FAMT 
(5 MBq/kg) and FDG (5 MBq/kg) after fasting for >6 h.
Image acquisition
PET/CT images were acquired at 1 h (60 ± 5 min) after 
injection using a Discovery STE PET/CT scanner (GE 
Healthcare, Milwaukee, WI) or a Biograph 16 PET/
CT scanner (Siemens, Malvern, PA) with 700-mm field 
of view (FOV) and a slice thickness of 3.27 mm. Three- 
dimensional (3D) data acquisition was performed for 
3 min per bed position, followed by image reconstruction 
with the 3D-ordered-subsets expectation maximization 
(3D-OSEM) method. Segmented attenuation was cor-
rected by X-ray CT (140  kV, 120–240  mAs) to produce 
128 × 128 matrix images. CT images were reconstructed 
using a conventional filtered back projection method. 
Axial full width at half-maximum (FWHM) at 1 cm from 
the center of FOV was 5.6 mm; the z-axis FWHM at 1 cm 
from the center of FOV was 6.3  mm. Intrinsic system 
sensitivity was 8.5  cps/kBq for 3D acquisition. Both the 
PET scanners were regularly calibrated with a phantom 
and their standardized uptake value (SUV) accuracy was 
routinely evaluated to ensure that the values produced 
were comparable. Patients were scanned from the thigh 
to the head in the arms-down position. No intravenous 
contrast material was administered for CT scanning. 
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Limited breath holding at normal expiration was used 
during CT to avoid motion-induced artifacts and allow 
co-registration of CT and PET images in the area of the 
diaphragm.
Data analysis
PET/CT images acquired using FDG and FAMT were 
interpreted by a single experienced nuclear medicine 
physician and were analyzed using a syngo MI Workplace 
(VA60C, Siemens AG, Munich, Germany). The reso-
lution of the reconstructed images was approximately 
5 mm at FWHM.
To evaluate the distribution of both the PET trac-
ers, the regions of interest (ROIs) were manually placed 
on each tumor lesion in the liver with assistance of CT 
images on the same slices, as well as on the normal liver 
parenchyma, back muscle, and mediastinum, which rep-
resented a blood pool by two experienced nuclear medi-
cine physicians. SUVs in ROIs were calculated using the 
following formula: SUV  =  [radioactive concentration 
in ROI (MBq/g)]/[injected dose (MBq)/patient’s body 
weight (g)].
Side-by-side review and analysis of radioactive images 
were performed to confirm that SUV was derived from 
the same lesion on both the PET scans. In this study, we 
employed SUVmax, which was defined as the peak SUV 
on the pixel with the highest count within ROI.
All tumor lesions were categorized by the histologi-
cal examination of the primary lesion or the liver biopsy 
specimen as adenocarcinoma (AC); squamous cell 
carcinoma (SCC); neuroendocrine tumor (NET; i.e., 
pheochromocytoma, malignant endocrine tumor, and 
paraganglioma); and carcinoid tumor (CAR). To evaluate 
the correlation between FDG and FAMT uptakes in liver 
lesions, three SUVmax-related parameters were ana-
lyzed; these were (1) SUVmax itself, (2) tumor-to-liver 
parenchymal (T/L) ratio, and (3) tumor-to-blood pool 
(T/B) ratio.
Statistical analysis
The correlation between FDG and FAMT uptakes in the 
metastatic liver lesions in each histological group was 
evaluated by linear regression analysis. The Mann–Whit-
ney U test was performed to evaluate the differences 
between each SUVmax parameter of FAMT and FDG. 
For all statistical analyses, p value <0.05 was considered 
statistically significant.
Results
The primary tumors were esophageal carcinoma 
(n = 10), lung carcinoma (n = 7), pancreatic carcinoma 
(n = 2), rectal carcinoid (n = 2), and one patient each for 
primary lesions in the gingiva, adrenal gland, and carotid 
body (Table  1). The median interval between FDG-PET 
and FAMT-PET was 7.6 days (range 1–30 days).
Tracer uptake in metastatic liver lesions and liver 
parenchymal tissue
A total of 59 lesions were detected on either FDG-PET or 
FAMT-PET in this study. Two lesions were not detected 
in FDG-PET/CT but were detected in FAMT-PET/CT. 
Fourteen lesions demonstrated opposing results with 
those of PET/CT; for these lesions, ROIs were carefully 
drawn while referring to PET with another tracer and 
enhanced CT images. On the basis of histological exami-
nations, primary lesions were divided into four forms 
(Table 1): SCC (n = 23), AC (n = 21), NET (n = 9), and 
CAR (n = 6).
SUVmax in these lesions ranged from 2.40 to 19.01 
(median 6.16) for FDG and from 1.02 to 3.85 (median 
1.85) for FAMT. As shown in Fig.  1, uptake of FAMT 
in metastatic lesions was significantly lower than that 
of FDG (p  <  0.001), whereas liver parenchymal tissue 
demonstrated an almost double SUVmax of FDG com-
pared with that of FAMT (p < 0.001); the median SUV-
max of 18F-FDG and 18F-FAMT in liver parenchymal 
tissue was 2.61 (range 1.36–4.50) and 1.39 (0.88–2.32), 
respectively.
Correlation between FDG and FAMT by each parameter
Scatter plots between FDG and FAMT by each param-
eter are shown in Fig. 2. No significant correlations in 
SUVmax (r = 0.167, p = 0.207); T/L ratio (r = 0.208, 
p  =  0.114); and T/B ratio (r  =  0.043, p  =  0.744) 
were observed. The distributions indicated that (1) 
CAR lesions had low FDG uptake and relatively high 
FAMT uptake; (2) NET showed low FAMT uptake 
and relatively high FDG uptake; (3) the T/L ratios of 
SCC tended to be higher than those of AC. Only two 
lesions of AC showed high FDG uptakes compared 
with SCC; these two lesions were derived from esoph-
ageal cancer.
Distribution of T/L ratio in each histological category
The distribution of T/L ratio demonstrated some tenden-
cies depending on the histological category, particularly 
for NET and CAR (Fig. 3). NETs had significantly lower 
T/L ratios for FAMT uptake (median 1.00; range 0.86–
1.34) compared with those for FDG uptake (median 2.86; 
range 1.70–6.13) (p < 0.01, Fig. 4a). CAR tumors tended 
to reveal lower T/L ratios for FDG uptake (median 1.10; 
range 0.78–1.92) than those for FAMT uptake (median 
1.80; range 0.80–2.34), but this was not significant 
(p = 0.345, Fig. 4b).
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Comparison of FDG and FAMT uptakes between SCC 
and AC (Figs. 5, 6)
The T/L ratio of SCC had median values of 3.50 (range 
1.09–6.02) on FDG-PET and 1.76 (range 0.92–2.69) on 
FAMT-PET. The T/L ratio of AC had median values of 
2.28 (range 1.43–6.96) on FDG-PET and 1.26 (range 
0.80–1.81) on FAMT-PET. Comparison of T/L ratios of 
SCC and AC revealed that FAMT uptake in the meta-
static liver lesions of SCC was higher than that of AC 
(p < 0.01). In contrast, FDG uptakes of SCC and AC were 
not significantly different (p = 0.235).
Discussion
The respective uptake of FAMT was lower in both meta-
static liver lesions and normal tissues compared with that 
of FDG. However, most liver metastases were recognized 
on FAMT-PET images, except NET lesions. Differential 
diagnosis among various tissues using T/L ratio might be 
useful, particularly for comparison between SCC and AC 
on FAMT-PET. In FDG and FAMT combinations, tissues 
tended to be distributed on the basis of their histology 
(Fig. 2).
Table 1 Characteristics of patients with liver metastasis
No. Age (years) Sex Primary tumor Lesion  
number
Size (cm) Histological type
1 59 M Pancreas 3 1.8–7.2 Adenocarcinoma
2 64 F Lung 3 2.4–3.1 Adenocarcinoma
3 83 M Rectum 3 2.0–11.0 Carcinoid
4 67 F Rectum 3 8.8–12.4 Carcinoid
5 61 M Esophagus 2 2.1–3.1 Squamous cell carcinoma
6 73 M Esophagus 3 1.8–7.7 Squamous cell carcinoma
7 60 F Lung 1 5.3 Adenocarcinoma
8 70 M Esophagus 3 1.0–1.7 Squamous cell carcinoma
9 73 M Lung 3 1.9–2.0 Adenocarcinoma
10 66 M Lung 3 2.0–3.0 Squamous cell carcinoma
11 53 M Lung 1 3.1 Adenocarcinoma
12 77 M Esophagus 3 1.6–2.2 Endocrine cell carcinoma
13 57 M Esophagus 3 7.5–11.8 Adenocarcinoma
14 65 F Adrenal gland 3 1.1–2.6 Malignant pheochromocytoma
15 67 M Esophagus 1 2.3 Squamous cell carcinoma
16 67 F Esophagus 3 8.3–10.6 Squamous cell carcinoma
17 74 M Lung 3 1.6–2.0 Adenocarcinoma
18 85 M Gingiva 3 2.4–4.8 Squamous cell carcinoma
19 32 M Lung 1 1.6 Adenocarcinoma
20 53 F Carotid body 3 2.4–4.4 Paraganglioma
21 84 M Esophagus 1 2.8 Squamous cell carcinoma
22 81 F Esophagus 3 2.6–6.3 Squamous cell carcinoma
23 56 M Pancreas 3 4.3–5.2 Adenocarcinoma
24 78 M Esophagus 1 10.0 Squamous cell carcinoma
Fig. 1 Comparison of FDG and FAMT by SUVmax in each area. FDG 
uptake showed significant differences between metastatic liver 
lesions (tumor) and the other areas without tumor involvement, 
specifically, normal liver parenchyma (liver), blood pool (blood), and 
muscle (p < 0.001, respectively). FDG uptake was significantly higher 
than that of FAMT in all areas. In the comparison with tumor and 
liver, SUVmax of FDG in tumor (median 6.16; range 2.40–19.01) was 
significant higher than that of FAMT (median 1.85; range 1.02–3.85). 
SUV standard uptake value, FDG 2-[18F]-fluoro-2-deoxyglucose, FAMT 
L-3-[18F] fluoro-alpha-methyl tyrosine
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Both FDG and FAMT uptakes for SCC were relatively 
higher than those for AC. Only two lesions of AC in one 
patient showed higher SUVmax compared with that 
in SCC; however, excluding these two lesions, the T/L 
ratio of FDG revealed no significant difference between 
SCC and AC (p = 0.063). This patient was the only case 
of esophageal adenocarcinoma. We speculated that this 
cancer lesion might have included adenosquamous com-
ponents. Further investigations of LAT1 expression based 
on histology will be required to demonstrate the utility of 
FDG-PET or FAMT-PET for differentiating between SCC 
and AC. FDG uptakes of CAR tumors had relatively low 
T/L ratios, resulting in difficulty to differentiate metastatic 
liver lesions from liver parenchymal tissues on FDG-PET. 
In contrast, CAR tumors were detected on FAMT-PET 
and FAMT-PET was superior to FDG-PET in this point.
In this study, FDG uptake in the liver parenchymal tis-
sues ranged from 1.36 to 4.50, and the median value of 
SUVmax (2.60) was already over the upper limit of the 
general threshold between benign and malignant lesions. 
FDG uptake in the liver parenchyma was higher than that 
of FAMT because glucose was metabolized and stored in 
the liver. In general, hepatocytes have glucose-6-phos-
phatase that can reverse FDG-6-phosphate to FDG, 
thus reducing FDG uptake in the hepatocyte (Torizuka 
et al. 1995; Khan et al. 2000; Yen et al. 2004). Therefore, 
FDG accumulation was relatively lower than what was 
expected of a glucose analog.
The differences between FDG and FAMT may be 
because of not only metabolism but also retention. 
Because FDG was taken up by GLUT1 and trapped into 
cells after phosphorylation, it accumulated in a linear 
Fig. 2 Dot plots of SUVmax, T/L ratio, T/B ratio, and T/M ratio. X axis shows the SUVmax of FAMT and the Y axis shows the SUVmax of FDG. No 
significant correlations of total lesions in a SUVmax, b T/L ratio, and c T/B ratio were observed (r = 0.167, p = 0.207; r = 0.208, p = 0.114; r = 0.043, 
p = 0.744, respectively). T/L ratio differed according to histological feature. SUV standard uptake value, FDG 2-[18F]-fluoro-2-deoxyglucose, FAMT L-3-
[18F] fluoro-alpha-methyl tyrosine, T/L tumor-to-liver parenchymal, T/B tumor-to-blood pool, SCC squamous cell carcinoma, AC adenocarcinoma, NET 
neuroendocrine tumor and pheochromocytoma, CAR carcinoid tumor
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fashion and was eventually retained. Conversely, after 
FAMT transport into cells by LAT1, relatively rapid 
clearance of FAMT can be observed in even tumor cells; 
this means that LAT1 function of FAMT transport was 
not one way but was reversible. These mechanisms may 
explain the lower SUVmax of FAMT.
Alpha-methylation of FAMT reduces liver accumula-
tion and increases renal excretion, whereas the analog 
of FAMT, l-tyrosine, has been well known to be one 
of the aromatic amino acids that are metabolized in 
the liver. This is an advantage of FAMT over the most 
commonly studied MET, which strongly accumulates 
in both the normal and metastatic liver tissues (Wiri-
yasermkul et  al. 2012). Another analog of tyrosine and 
a well-known amino acid tracer, O-(2-18F-fluoroethyl)-
l-tyrosine (FET), has been shown to have low accumu-
lation in murine liver and a higher specificity than FDG 
(Ishiwata et  al. 2004). Although FET would be a good 
candidate for detecting liver metastasis, most reports on 
its application were for brain tumors, and there has been 
no report on liver metastasis.
Wiriyasermkul et  al. (2012) revealed that FAMT had 
two potential benefits: one was the reduced uptake in 
the liver and another was the specific transport via LAT1 
without the need to go through other types of amino acid 
transporters, such as the system ASC amino acid trans-
porter-2 (ASCT2). The details of the mechanisms for 
uptake of FAMT or methionine in normal liver are not 
clear; however, FAMT is transported only via L-amino 
acid transporter-1 (LAT1), while methionine is trans-
ported via LAT-1, LAT-2, and some other transport-
ers (Singhal et al. 2008). LAT1 specificity of FAMT may 
increase the possibility of detecting metastatic liver 
lesions.
Nevertheless, because FDG strongly accumulated in 
the metastatic liver lesions, T/L ratios were still higher 
than those of FAMT. In this study, T/L ratio indicated the 
specific features based on histological origins. Although 
FAMT uptake was detected in metastatic liver lesions 
from NETs, FDG accumulation was very high (median; 
7.28, ranging from 5.50 to 12.45). Our clinical experi-
ences revealed that FAMT-PET had a difficulty in the 
Fig. 3 PET/CT fusion images with either FDG or FAMT administration for the same patients with NET or CAR. For a patient with NET, FDG PET 
images showed high spotty accumulations (arrow) in the liver (a). No FAMT uptakes were seen in the liver (b). For a patient with CAR, FDG PET 
showed diffuse uptake for normal liver parenchyma without uptakes for tumor lesion in the liver (c). FAMT PET showed some faint massive uptakes 
(arrow) of FAMT in the liver (d). FDG 2-[18F]-fluoro-2-deoxyglucose, FAMT L-3-[18F] fluoro-alpha-methyl tyrosine, T/L tumor-to-liver parenchymal, CAR 
carcinoid tumor, NET neuroendocrine tumor and pheochromocytoma
Page 7 of 9Kodaira et al. SpringerPlus  (2016) 5:618 
detecting pheochromocytoma lesions (unpublished 
data), whereas FDG had an advantage. In contrast, the 
detection of liver metastasis from CAR tumors using 
FDG-PET was difficult because FDG uptake was low; 
thus, for these lesions, FAMT-PET could be more use-
ful. According to the International Union Against Cancer 
classification of neuroendocrine tumors, CAR belongs to 
G1 and NET belongs to G2 or G3. Because the uptake of 
FDG generally reflects the grading of tumor differentia-
tion, FDG-PET should have shown higher accumulations 
in NET than in CAR. Low-grade tumors, such as NET, 
show a high uptake of FDG compared with well-differen-
tiated tumors such as CAR. In our case, two lesions were 
detected using only FAMT-PET not FDG-PET.
The limitation of this study was that patients with colo-
rectal cancer were not included. Although most meta-
static liver lesions from colorectal cancer would be AC, 
our AC group included metastasis from lung cancers. 
However, some reports revealed high expressions of 
GLUT1 and high FDG uptake in SCC (Yen et  al. 2004; 
Fig. 4 Comparison between FDG an FAMT in terms of T/L ratio in 
NET lesions and CAR lesions. a T/L ratio of FAMT uptake was signifi-
cantly lower than that of FDG in the group of NET lesions (p < 0.01).  
b T/L ratio of FAMT (median 1.80) was slightly higher than that of FDG 
(median 1.10), but not significant (p = 0.345). FDG 2-[18F]-fluoro-2-de-
oxyglucose, FAMT L-3-[18F] fluoro-alpha-methyl tyrosine, T/L tumor-to-
liver parenchymal, CAR carcinoid tumor, NET neuroendocrine tumor 
and pheochromocytoma
Fig. 5 Comparison of T/L ratios in FDG and FAMT between SCC and 
AC. a FDG uptakes in liver metastasis from SCC were higher than 
those from AC (p < 0.05). b FAMT uptakes for SCC and AC were not 
significantly different (p = 0.235). FDG 2-[18F]-fluoro-2-deoxyglucose, 
FAMT L-3-[18F] fluoro-alpha-methyl tyrosine, T/L tumor-to-liver paren-
chyma, T/B tumor-to-blood pool, SCC squamous cell carcinoma, AC 
adenocarcinoma
Fig. 6 PET images of patients with either SCC or AC. PET images 
were acquired from two patients with metastases of SCC (a, c) and AC 
(b, d). High FDG uptakes were seen in the liver (a, b) while weak to 
high FAMT uptakes were seen in the liver (c, d). Normal liver uptakes 
of FAMT were weaker than those of FDG. FDG 2-[18F]-fluoro-2-deoxy-
glucose, FAMT L-3-[18F] fluoro-alpha-methyl tyrosine, SCC squamous 
cell carcinoma, AC adenocarcinoma
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Fletcher et al. 2008). Our comparison between SCC and 
AC may not be different from that for colorectal cancer. 
FAMT-PET was performed not for conventional clinical 
examinations but for study purposes; this study did not 
include metastatic liver lesions from colorectal cancers. 
Therefore, the number of patients who underwent both 
FDG-PET and FAMT-PET was small, and this would be 
a limitation for statistical analysis. In further investiga-
tions, the time of PET acquisition after tracer adminis-
tration can be changed to an earlier time. It would have 
an advantage with obtaining high FAMT uptakes in liver 
lesions. However, the high T/L ratio would be required 
to depict liver lesions more clearly. Because of the back-
ground signals, including normal liver uptakes is another 
important factor and should be investigated for an opti-
mal time.
Conclusion
There is no general advantage in use of FAMT-PET 
over that offered by FDG for detecting liver metastasis. 
However, since FAMT-PET could detect metastatic liver 
lesions from many types of cancers, except NET, histo-
logical tendencies were shown by comparisons between 
PET studies of FDG and FAMT.
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